Evidence for cyclophosphamide-induced transitional cell carcinoma in a renal transplant patient

T. M. Tuttle, G. M. Williams, F. F. Marshall

Research output: Contribution to journalArticlepeer-review

Abstract

Cyclophosphamide treatment has been associated with bladder cancer in a number of case reports but no causal relationship has been proved since nearly all of these patients were treated with the drug for malignant disease. We describe a patient who received cyclophosphamide after cadaveric renal transplantation to prevent rejection. Transitional cell carcinoma developed in the native bladder and in the donor transplanted ureter (20-year-old donor) 13 years later despite no identifiable risk factors. This case strengthens the argument that cyclophosphamide has a carcinogenic potential on the urinary tract epithelium.

Original languageEnglish (US)
Pages (from-to)1009-1011
Number of pages3
JournalJournal of Urology
Volume140
Issue number5 PART I
DOIs
StatePublished - 1988

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Evidence for cyclophosphamide-induced transitional cell carcinoma in a renal transplant patient'. Together they form a unique fingerprint.

Cite this